AAAAAA

   
Results: 1-13 |
Results: 13
THYMIC ANTITUMOR EFFECTORS IN MICE CURED OF LYMPHOMA BY CYCLOPHOSPHAMIDE PLUS TNF-ALPHA THERAPY - PHENOTYPIC AND FUNCTIONAL-CHARACTERIZATION UP TO 20 MONTHS AFTER INITIAL TUMOR INOCULATION
Authors: EHRKE MJ VERSTOVSEK S POCCHIARI SK KRAWCZYK CM UJHAZY P ZALESKIS G MACCUBBIN DL MEER JM MIHICH E
Citation: Mj. Ehrke et al., THYMIC ANTITUMOR EFFECTORS IN MICE CURED OF LYMPHOMA BY CYCLOPHOSPHAMIDE PLUS TNF-ALPHA THERAPY - PHENOTYPIC AND FUNCTIONAL-CHARACTERIZATION UP TO 20 MONTHS AFTER INITIAL TUMOR INOCULATION, International journal of cancer, 76(4), 1998, pp. 579-586
EXPRESSION OF B-CELL MARKERS ON SR-4987 CELLS DERIVED FROM MURINE BONE-MARROW STROMA
Authors: PESSINA A NERI MG MINEO E PICCIRILLO M GRIBALDO L BRAMBILLA P ZALESKIS G UJHAZY P
Citation: A. Pessina et al., EXPRESSION OF B-CELL MARKERS ON SR-4987 CELLS DERIVED FROM MURINE BONE-MARROW STROMA, Experimental hematology, 25(6), 1997, pp. 536-541
SPECIFIC ANTI-EL4-LYMPHOMA IMMUNITY IN MICE CURED 2 YEARS EARLIER WITH DOXORUBICIN AND INTERLEUKIN-2
Authors: EHRKE MJ VERSTOVSEK S ZALESKIS G HO RLX UJHAZY P MACCUBBIN DL MIHICH E
Citation: Mj. Ehrke et al., SPECIFIC ANTI-EL4-LYMPHOMA IMMUNITY IN MICE CURED 2 YEARS EARLIER WITH DOXORUBICIN AND INTERLEUKIN-2, Cancer immunology and immunotherapy, 42(4), 1996, pp. 221-230
DOXORUBICIN AND CYCLOSPORINE-A AFFECT MURINE LYMPHOID-CELLS EXPRESSING DIFFERENT ANTIGENIC DETERMINANTS
Authors: ZALESKIS G VERSTOVSEK S TZAI TS MIHICH E EHRKE MJ
Citation: G. Zaleskis et al., DOXORUBICIN AND CYCLOSPORINE-A AFFECT MURINE LYMPHOID-CELLS EXPRESSING DIFFERENT ANTIGENIC DETERMINANTS, Oncology research, 7(6), 1995, pp. 307-315
EXPRESSION OF CD ANTIGEN ON SR-4987 MURINE MARROW STROMAL CELLS
Authors: PESSINA A ZALESKIS G MINEO E CERRI A NERI MG
Citation: A. Pessina et al., EXPRESSION OF CD ANTIGEN ON SR-4987 MURINE MARROW STROMAL CELLS, Journal of experimental & clinical cancer research, 14(1), 1995, pp. 197-198
CYCLOPHOSPHAMIDE PLUS TUMOR-NECROSIS-FACTOR-ALPHA CHEMOIMMUNOTHERAPY CURED MICE - LIFELONG IMMUNITY AND REJECTION OF RE-IMPLANTED PRIMARY LYMPHOMA
Authors: EHRKE MJ VERSTOVSEK S KRAWCZYK CM UJHAZY P ZALESKIS G MACCUBBIN DL MIHICH E
Citation: Mj. Ehrke et al., CYCLOPHOSPHAMIDE PLUS TUMOR-NECROSIS-FACTOR-ALPHA CHEMOIMMUNOTHERAPY CURED MICE - LIFELONG IMMUNITY AND REJECTION OF RE-IMPLANTED PRIMARY LYMPHOMA, International journal of cancer, 63(3), 1995, pp. 463-471
INTRACELLULAR DOXORUBICIN KINETICS IN LYMPHOMA-CELLS AND LYMPHOCYTES INFILTRATING THE TUMOR AREA IN-VIVO - A FLOW CYTOMETRIC STUDY
Authors: ZALESKIS G HO RLX DIEGELMAN P MACCUBBIN D UJHAZY P MIHICH E EHRKE MJ
Citation: G. Zaleskis et al., INTRACELLULAR DOXORUBICIN KINETICS IN LYMPHOMA-CELLS AND LYMPHOCYTES INFILTRATING THE TUMOR AREA IN-VIVO - A FLOW CYTOMETRIC STUDY, Oncology research, 6(4-5), 1994, pp. 183-194
LIPOPOLYSACCHARIDE AND SPLENIC TUMORICIDAL MACROPHAGE ACTIVATION
Authors: VERSTOVSEK S ZALESKIS G MACCUBBIN DL MIHICH E EHRKE MJ
Citation: S. Verstovsek et al., LIPOPOLYSACCHARIDE AND SPLENIC TUMORICIDAL MACROPHAGE ACTIVATION, Journal of leukocyte biology, 56(6), 1994, pp. 714-722
DOXORUBICIN-INDUCED DNA-DEGRADATION IN MURINE THYMOCYTES
Authors: ZALESKIS G BERLETH E VERSTOVSEK S EHRKE MJ MIHICH E
Citation: G. Zaleskis et al., DOXORUBICIN-INDUCED DNA-DEGRADATION IN MURINE THYMOCYTES, Molecular pharmacology, 46(5), 1994, pp. 901-908
EFFECT OF PERIOPERATIVE CHEMOIMMUNOTHERAPY WITH CYCLOPHOSPHAMIDE AND AUTOLOGOUS TUMOR VACCINE IN MURINE MBT-2 BLADDER-CANCER
Authors: TZAI TS HUBEN RP ZALESKIS G BERLETH ES EHRKE MJ MIHICH E
Citation: Ts. Tzai et al., EFFECT OF PERIOPERATIVE CHEMOIMMUNOTHERAPY WITH CYCLOPHOSPHAMIDE AND AUTOLOGOUS TUMOR VACCINE IN MURINE MBT-2 BLADDER-CANCER, The Journal of urology, 151(6), 1994, pp. 1680-1686
IMMUNOLOGICAL RESPONSES CRITICAL TO THE THERAPEUTIC EFFECTS OF ADRIAMYCIN PLUS INTERLEUKIN-2 IN C57BL 6 MICE BEARING SYNGENEIC EL4 LYMPHOMA/
Authors: HO RLX MACCUBBIN DL UJHAZY P ZALESKIS G EPPOLITO C MIHICH E EHRKE MJ
Citation: Rlx. Ho et al., IMMUNOLOGICAL RESPONSES CRITICAL TO THE THERAPEUTIC EFFECTS OF ADRIAMYCIN PLUS INTERLEUKIN-2 IN C57BL 6 MICE BEARING SYNGENEIC EL4 LYMPHOMA/, Oncology research, 5(9), 1993, pp. 363-372
DEVELOPMENT OF A SAFE AND EFFECTIVE ADRIAMYCIN PLUS INTERLEUKIN-2 THERAPY AGAINST BOTH ADRIAMYCIN-SENSITIVE AND ADRIAMYCIN-RESISTANT LYMPHOMAS
Authors: HO RLX MACCUBBIN D ZALESKIS G KRAWCZYK C WING K MIHICH E EHRKE MJ
Citation: Rlx. Ho et al., DEVELOPMENT OF A SAFE AND EFFECTIVE ADRIAMYCIN PLUS INTERLEUKIN-2 THERAPY AGAINST BOTH ADRIAMYCIN-SENSITIVE AND ADRIAMYCIN-RESISTANT LYMPHOMAS, Oncology research, 5(9), 1993, pp. 373-381
DIFFERENTIAL-EFFECTS OF CYCLOPHOSPHAMIDE (CY) ALONE AND IN COMBINATION WITH TUMOR-NECROSIS-FACTOR (TNF) ON MURINE THYMOCYTES
Authors: POCCHIARI S EHRKE MJ MIHICH E ZALESKIS G
Citation: S. Pocchiari et al., DIFFERENTIAL-EFFECTS OF CYCLOPHOSPHAMIDE (CY) ALONE AND IN COMBINATION WITH TUMOR-NECROSIS-FACTOR (TNF) ON MURINE THYMOCYTES, The Journal of immunology, 150(8), 1993, pp. 109-109
Risultati: 1-13 |